The international prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes in non-surgical bleeding episodes in Glanzmann thrombasthenia patients

Disclosures: GDM has been a speaker or a member of a speakers bureau for Boehringer Ingelheim, Sanofi-Aventis, Bayer, Novo Nordisk, Pfizer, Biotest, and Grifols, and has also acted as a consultant or ad hoc speaker/consultant for Boehringer Ingelheim, Eli Lilly, Sanofi-Aventis, Bayer, CSL Behring, Novo Nordisk, Pfizer, Biotest, and Grifols. RBZ has been a speaker for Sanofi-Aventis, LEO Pharma, GlaxoSmithKline, Bayer, Boehringer Ingelheim, Pfizer, Novo Nordisk, CSL Behring, MEDA, Novartis, Octapharma, Biotest, Wyeth, and AstraZeneca, and received fees from Biotest, CSL Behring, GlaxoSmithKline, Novartis, Sanofi-Aventis, and Wyeth. He is a member of the advisory boards at Novo Nordisk, Pfizer, and Bayer. He received research funding from CSL Behring. Rd'O received fees or honoraria for attending advisory boards, or speaking at symposia from Baxter, Novo Nordisk, Bayer, Pfizer, Sobi and CSL Behring. NB is an employee of Larix A/S, a clinical research organization employed by Novo Nordisk. MNDDM has acted as paid lecturer or board member and received funds for researches unrelated to the present study from Pfizer, Bayer, Biotest and Novo Nordisk in the previous 36 months. MCP was chair of Novo Nordisk’s expert panel on Glanzmann Thrombasthenia Registry, has been an ad hoc speaker for Bayer, Novo Nordisk, and Pfizer, and attended advisory board meetings of Biogen Idec, CSL Behring, Novo Nordisk, Octapharma, and Pfizer, and received grant funding from CSL Behring.

Contributions: GDM, RBZ, Rd'O, and MCP participated in the planning, data monitoring of the Glanzmann Thrombasthenia Registry, all authors participated in data analysis with NB and MNDDM providing the statistical analytical expertise. MCP wrote the initial manuscript and all authors contributed equally to the revision, finalization, and approval of the manuscript.